Invion Limited is an Australia-based life sciences company. The Company is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The Company is engaged in the clinical development of a PhotoDynamic Therapy (PDT) for cancer. Its photosensitizer (the agent used in PDT) is called IVX-PDT and is based on Photosoft Technology. Its PDT is an alternative to surgery, and in contrast to radiotherapy and chemotherapy, which are immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumor by leukocytes. It produces topical and intravenous products suitable for use in skin cancer and in solid tumors, such as those present in ovarian, prostate and lung cancer. It is developing a topical formulation of its photosensitizing agent, IVX-PDT, to treat superficial Basal Cell Carcinoma (sBCC), Actinic Keratosis (AK) and Squamous Cell Cancer (SCC).
INVION LIMITED 
